ortataxel Report issue

Small molecule Experimental First in Class
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ortataxel is a drug used in chemotherapy. As of June 2009, Spectrum Pharmaceuticals has the drug in a Phase 2 clinical trial.   Wikipedia

Chemistry

  • SMILES: CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2
  • InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
  • Mol. Mass: 378.43
  • ALogP: 2.99
  • ChEMBL Molecules:
    finerenone  
    ortataxel  
More Chemistry

Pharmacology

Alternative names

13-(n-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxy-baccatin-1,14-carbonate | 13-(n-tert-butoxycarbonyl-beta-isobutyisoserinyl)-14-hydroxybaccatin-1,14-carbonate | bay 59-8862 | bay-59-8862 | bay59-8862 | bay 94-8862 | bay94-8862 | idn 5109 | ind5109 | ortataxel | sb-t-101131

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Diabetic Nephropathies (Phase 2)

Glioblastoma (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue